CNE100003M51
CNE100003M51
GUANGDONG MARUBI BIOTECHNOLOGY
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 11.67B EUR | 11.28B EUR | 10.63B EUR | 13.29B EUR |
Enterprise Value | 10.27B EUR | 10.27B EUR | 9.79B EUR | 12.44B EUR |
Valuation Multiples | ||||
Trailing P/E | 50.17x | 71.05x | 68.53x | 70.3x |
Forward P/E | 33.65x | -- | -- | -- |
Price to Sales | 3.48x | 4.22x | 3.78x | 4.78x |
Price to Book | 3.45x | 3.34x | 3.1x | 3.99x |
EV/Revenue | 3.06x | 3.84x | 3.48x | 4.48x |
EV/EBITDA | 49.68x | 48.05x | 43.46x | 46.67x |
Price to FCF (P/FCF) | 104.73x | 182.97x | 76.63x | 161.7x |
EV/FCF | 92.15x | 166.56x | 70.62x | 151.33x |
FCF Yield | 0.95% | 0.55% | 1.3% | 0.62% |